Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 06:00 ET | Source: Draig Therapeutics

Draig Therapeutics Appoints Seasoned Neuroscience Leader Ivana Magovčević-Liebisch as President and Chief Executive Officer

Dr Magovčević-Liebisch is an accomplished pharmaceutical and biotechnology executive with over 25 years of leadership experienceDr Ruth McKernan FMedSci CBE, co-founder and Interim CEO, will continue...
October 02, 2025 07:00 ET | Source: Draig Therapeutics

Draig Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study of DT-101 for the Treatment of Major Depressive Disorder

DT-101 is designed to allow effective modulation of the AMPA receptor without compromising safetyPhase 2 clinical trial initiation anticipated before the end of 2025Trial builds on positive Phase 1...
July 15, 2025 04:00 ET | Source: Draig Therapeutics

Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors

Strong track record at executive and board level of building company value across all stages of development including supporting the development of multiple blockbuster medicines Cardiff, United...
June 18, 2025 00:00 ET | Source: Draig Therapeutics

Draig Therapeutics Launches with $140 Million (£107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric Disorders

Clinical-stage company led by world-class team targeting core neurotransmission pathways underlying neuropsychiatric disorders with a rich pipeline of novel, potentially transformative...
March 18, 2025 08:00 ET | Source: Alzamend Neuro, Inc.

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial for Next-Gen Lithium Treatment of Major Depressive Disorder at Mass. General Hospital
February 25, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight

New York, USA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight The depression treatment market is...
September 18, 2024 07:00 ET | Source: Engrail Therapeutics, Inc.

Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia

Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia
March 19, 2024 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
November 16, 2023 13:00 ET | Source: DelveInsight Business Research LLP

Major Depressive Disorder Market to Register Stunning Growth During the Forecast Period (2023–2032), Examines DelveInsight | Leading Companies - Otsuka, Sumitomo, COMPASS, Sage, Neurocrine, Boehringer Ingelheim, Janssen

New York, USA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Major Depressive Disorder Market to Register Stunning Growth During the Forecast Period (2023–2032), Examines DelveInsight | Leading Companies -...
October 09, 2023 08:30 ET | Source: ABVC BioPharma, Inc.

ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)

The Company Holds a US Patent for the Same Treatment FREMONT, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage...